Prostate Cancer

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

CAPTAIN trial data showed TULSA preserved penile length, continence, and erectile function compared with robotic prostatectomy in localized prostate cancer.

The PDUFA target action date is in the fourth quarter of 2026.

Olaparib's indications in the US include use as a single agent for patients with HRR gene-mutated mCRPC and in combination with abiraterone and prednisone for patients with BRCA-mutated mCRPC.

These results provided the basis for the ongoing randomized phase 3 ProstACT Global trial evaluating 177Lu-rosopatamab tetraxetan in mCRPC.

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, discusses the clinical significance of the phase 3 PROTEUS trial and addresses concerns about the study's use of ADT in the control arm.

Jamie Michael, MD, highlights a study exploring the impact of MRI and genomics on "extreme" grade reclassification in men on active surveillance.

The phase 2 study is assessing whether an adaptive treatment approach can improve responses and enable treatment pauses for select patients.

The pivotal phase 3 Himalayas-1 trial will evaluate rinzimetostat plus darolutamide vs with physician's choice of an ARPI or docetaxel.

According to the authors, the findings lay the groundwork for future work of genomics-guided treatment de-escalation in prostate cancer.

In this episode, Badrinath R. Konety, MBBS, walks through key recommendations from the 2026 AUA/SUO Early Detection of Prostate Cancer Guideline amendment.

The phase 1 trial is assessing the safety and preliminary antitumor activity of actinium (225Ac) rhPSMA-10.1 injection.

In this episode, Anup A. Vora, MD, discusses patient selection for focal therapy in localized prostate cancer, the role of precision medicine, and how advanced practice providers are helping deliver comprehensive, patient-centered GU oncology care.

A recent meta-analysis suggests that the Prolaris combined clinical risk score is prognostic across NCCN risk groups in men with localized prostate cancer.

These results are intended to support a premarket approval submission for an expanded indication of the Vanquish device for the management of clinically localized prostate cancer.

Interim results from the phase 2 CONVERGE-01 trial showed encouraging antitumor activity and a manageable safety profile with Ac-225 rosopatamab tetraxetan in mCRPC.

The tentative approval spans tablets in 40-mg, 80-mg, 120-mg, and 160-mg strengths.

In this episode of The UroOnc Minute, Adam B. Weiner, MD, is joined by Keyan Salari, MD, PhD, to examine the results of the PROTEUS trial and their implications for managing high-risk localized prostate cancer.

The following FAQs highlight key recommendations and practical takeaways from the 2026 AUA/SUO Advanced Prostate Cancer Guideline.

Enzalutamide plus talazoparib showed promising clinical activity in high-volume mHSPC, although with a notable toxicity burden.

Preston C. Sprenkle, MD, discusses the unmet needs, emerging solutions, and longer-term vision for MRI in prostate cancer care.

In this episode of The UroOnc Minute, Lourdes Guerrios-Rivera, MD, discusses strategies to improve patient engagement and adherence during active surveillance for prostate cancer, highlighting the critical roles of education, communication, and structured follow-up.

Daniel J. George, MD, discusses the clinical significance of the FDA approval of capivasertib, practical considerations for PTEN testing and toxicity management, and the broader implications of precision medicine for patients with advanced prostate cancer.

The approval is supported by data from the phase 3 CAPItello-281 trial.